Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$16.57
0.774.87%
At close: -
$16.75
0.181.08%
After Hours: 4:40 PM EDT
Comments
Loading...
ARS Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:SPRY | Benzinga
ARS Pharmaceuticals Inc has a consensus price target of $24.67 based on the ratings of 7 analysts. The high is $30 issued by Scotiabank on March 7, 2025. The low is $14 issued by SVB Leerink on December 13, 2022. The 3 most-recent analyst ratings were released by Scotiabank, Raymond James, and Leerink Partners on March 7, 2025, January 14, 2025, and January 13, 2025, respectively. With an average price target of $28.33 between Scotiabank, Raymond James, and Leerink Partners, there's an implied 69.17% upside for ARS Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
Raymond James
Leerink Partners
Cantor Fitzgerald
Wedbush
1calculated from analyst ratings
Analyst Ratings for ARS Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/07/2025 | Buy Now | 79.12% | Scotiabank | Louise Chen56% | → $30 | Initiates | → Sector Outperform | Get Alert |
| 01/14/2025 | Buy Now | 67.18% | Raymond James | Ryan Deschner70% | $26 → $28 | Maintains | Strong Buy | Get Alert |
| 01/13/2025 | Buy Now | 61.21% | Leerink Partners | Roanna Ruiz38% | $26 → $27 | Maintains | Outperform | Get Alert |
| 10/08/2024 | Buy Now | 79.12% | Cantor Fitzgerald | Josh Schimmer57% | $30 → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 09/20/2024 | Buy Now | 49.27% | Leerink Partners | Roanna Ruiz38% | $21 → $25 | Maintains | Outperform | Get Alert |
| 09/16/2024 | Buy Now | 79.12% | Cantor Fitzgerald | Josh Schimmer57% | $30 → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 79.12% | Cantor Fitzgerald | Josh Schimmer57% | $30 → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 08/20/2024 | Buy Now | 79.12% | Cantor Fitzgerald | Josh Schimmer57% | → $30 | Initiates | → Overweight | Get Alert |
| 08/13/2024 | Buy Now | 31.36% | Raymond James | Ryan Deschner70% | $18 → $22 | Upgrade | Outperform → Strong Buy | Get Alert |
| 07/25/2024 | Buy Now | 7.47% | Raymond James | Ryan Deschner70% | → $18 | Initiates | → Outperform | Get Alert |
| 03/11/2024 | Buy Now | 13.45% | Wedbush | Andreas Argyrides70% | $19 → $19 | Reiterates | Outperform → Outperform | Get Alert |
| 03/05/2024 | Buy Now | 7.47% | Leerink Partners | Roanna Ruiz38% | $6 → $18 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/13/2023 | Buy Now | -22.38% | Wedbush | Andreas Argyrides70% | $5 → $13 | Maintains | Outperform | Get Alert |
| 09/21/2023 | Buy Now | -70.15% | Wedbush | Andreas Argyrides70% | $15 → $5 | Maintains | Outperform | Get Alert |
| 09/20/2023 | Buy Now | — | William Blair | Tim Lugo31% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 08/14/2023 | Buy Now | -10.44% | Wedbush | Andreas Argyrides70% | → $15 | Reiterates | Outperform → Outperform | Get Alert |
| 06/21/2023 | Buy Now | -10.44% | Wedbush | Andreas Argyrides70% | $17 → $15 | Maintains | Outperform | Get Alert |
| 05/18/2023 | Buy Now | 1.5% | Wedbush | Andreas Argyrides70% | → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 05/12/2023 | Buy Now | 1.5% | Wedbush | Andreas Argyrides70% | → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 05/10/2023 | Buy Now | 1.5% | Wedbush | Andreas Argyrides70% | → $17 | Reiterates | → Outperform | Get Alert |
| 01/31/2023 | Buy Now | -40.29% | Wedbush | Andreas Argyrides70% | → $10 | Initiates | → Outperform | Get Alert |
| 01/04/2023 | Buy Now | — | William Blair | Tim Lugo31% | — | Initiates | → Outperform | Get Alert |
| 12/13/2022 | Buy Now | -16.41% | SVB Leerink | Roanna Ruiz38% | → $14 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for ARS Pharmaceuticals (SPRY) stock?
The latest price target for ARS Pharmaceuticals (NASDAQ:SPRY) was reported by Scotiabank on March 7, 2025. The analyst firm set a price target for $30.00 expecting SPRY to rise to within 12 months (a possible 79.12% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ARS Pharmaceuticals (SPRY)?
The latest analyst rating for ARS Pharmaceuticals (NASDAQ:SPRY) was provided by Scotiabank, and ARS Pharmaceuticals initiated their sector outperform rating.
When was the last upgrade for ARS Pharmaceuticals (SPRY)?
The last upgrade for ARS Pharmaceuticals Inc happened on August 13, 2024 when Raymond James raised their price target to $22. Raymond James previously had an outperform for ARS Pharmaceuticals Inc.
When was the last downgrade for ARS Pharmaceuticals (SPRY)?
The last downgrade for ARS Pharmaceuticals Inc happened on September 20, 2023 when William Blair changed their price target from N/A to N/A for ARS Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for ARS Pharmaceuticals (SPRY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ARS Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ARS Pharmaceuticals was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.
Is the Analyst Rating ARS Pharmaceuticals (SPRY) correct?
While ratings are subjective and will change, the latest ARS Pharmaceuticals (SPRY) rating was a initiated with a price target of $0.00 to $30.00. The current price ARS Pharmaceuticals (SPRY) is trading at is $16.75, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
